Literature DB >> 20026759

Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation.

Els Moltzer1, Anna V A Verkuil, Richard van Veghel, A H Jan Danser, Joep H M van Esch.   

Abstract

Because angiotensin (Ang) metabolites mediate functions independent of Ang II, we investigated their effects on coronary flow in spontaneously hypertensive rats (SHRs). Results were compared with those in the iliac artery and abdominal aorta and the coronary circulation of the Wistar rat. Ang II, III, and IV decreased coronary flow in SHRs and Wistar rats, with Ang III and IV being approximately 10 and approximately 1000 times less potent than Ang II. Ang-(1-7) decreased coronary flow at concentrations >1 micromol/L in SHRs. The Ang II type 1 receptor antagonist irbesartan blocked the effects of Ang II, III, and IV, whereas the Ang II type 2 receptor antagonist PD123319 blocked the effects of Ang-(1-7). The maximal Ang II- and III-induced decreases in coronary flow in SHRs were twice as large as those in Wistar rats. PD123319 enhanced the constrictor effects of Ang II and III in Wistar rats so that, in the presence of this drug, their effects were comparable to those in SHRs. In contrast, PD123319 did not alter the Ang II- and III-induced responses in SHRs and blocked the constrictor effect of Ang II in iliac arteries. Ang II type 2 receptor-mediated relaxation did not occur in iliac arteries and abdominal aortas, and the constrictor effects of Ang metabolites in these vessels were identical in Wistar rats and SHRs. In conclusion, coronary constriction induced by Ang II, Ang III, and Ang-(1-7) is enhanced in SHRs as compared with Wistar rats. This is attributable to the absence of counterregulatory Ang II type 2 receptor-mediated relaxation and/or a change of the Ang II type 2 receptor phenotype from relaxant to constrictor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20026759     DOI: 10.1161/HYPERTENSIONAHA.109.145037

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  22 in total

Review 1.  Angiotensin receptor blockers and tumorigenesis: something to be (or not to be) concerned about?

Authors:  Vadim Tchaikovski; Gregory Y H Lip
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

Review 2.  New insights into angiotensin receptor actions: from blood pressure to aging.

Authors:  Johannes Stegbauer; Thomas M Coffman
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-01       Impact factor: 2.894

3.  Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.

Authors:  Lodi C W Roksnoer; Richard van Veghel; René de Vries; Ingrid M Garrelds; Usha M Bhaggoe; Edith C H Friesema; Frank P J Leijten; Marko Poglitsch; Oliver Domenig; Marian C Clahsen-van Groningen; Ewout J Hoorn; A H Jan Danser; Wendy W Batenburg
Journal:  Kidney Int       Date:  2015-04-01       Impact factor: 10.612

Review 4.  2010 position paper of the Italian Society of Hypertension (SIIA): angiotensin receptor blockers and risk of cancer.

Authors:  Massimo Volpe; Alberto Morganti
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-03-01

5.  Angiotensin II and oxidative stress in the failing heart.

Authors:  Daniela Zablocki; Junichi Sadoshima
Journal:  Antioxid Redox Signal       Date:  2012-05-03       Impact factor: 8.401

Review 6.  Update on the angiotensin AT(2) receptor.

Authors:  Claudia A McCarthy; Robert E Widdop; Kate M Denton; Emma S Jones
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

Review 7.  The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia.

Authors:  Langeza Saleh; Koen Verdonk; Willy Visser; Anton H van den Meiracker; A H Jan Danser
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-01-10

Review 8.  Are the antagonists of the renin-angiotensin system also anticancer agents?

Authors:  Chiara Lonati; Alberto Morganti
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-06-11

Review 9.  Key developments in renin-angiotensin-aldosterone system inhibition.

Authors:  Bruno Sevá Pessôa; Nils van der Lubbe; Koen Verdonk; Anton J M Roks; Ewout J Hoorn; A H Jan Danser
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

Review 10.  Angiotensin II type-2 receptor-specific effects on the cardiovascular system.

Authors:  Ying Li; Xiao-Hui Li; Hong Yuan
Journal:  Cardiovasc Diagn Ther       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.